BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37301259)

  • 1. Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.
    Grambozov B; Kalantari F; Beheshti M; Stana M; Karner J; Ruznic E; Zellinger B; Sedlmayer F; Rinnerthaler G; Zehentmayr F
    Radiother Oncol; 2023 Aug; 185():109728. PubMed ID: 37301259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of the Volumetric Parameters of Dual-Time-Point
    Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H
    AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426
    [No Abstract]   [Full Text] [Related]  

  • 10. Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer.
    Wang D; Koh ES; Descallar J; Pramana A; Vinod SK; Ho Shon I
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):349-358. PubMed ID: 27550522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy.
    Shrestha S; Higuchi T; Shirai K; Tokue A; Shrestha S; Saitoh JI; Hirasawa H; Ohno T; Nakano T; Tsushima Y
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1220-1227. PubMed ID: 31758225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
    Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of
    Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Volumetric Parameters on Staging and Posttreatment FDG PET/CT in Patients With Stage IV Non-Small Cell Lung Cancer.
    Lee JW; Lee SM; Yun M; Cho A
    Clin Nucl Med; 2016 May; 41(5):347-53. PubMed ID: 26825204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
    Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 18. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
    Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
    Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
    Yanarateş A; Yazici B
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.